{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-000778","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.544868+00:00","generated_at":"2026-05-16T11:01:51.038912+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Insmed reports BRINSUPRI 2025 revs $172.7M; ARIKAYCE $433.8M; guides 2026 pipeline milestones","bullets":["BRINSUPRI total revenues ~$172.7M for 2025 (~$144.6M in Q4 alone); ~4,000 prescribers, ~9,000 new patients in Q4.","ARIKAYCE global revenues ~$433.8M in 2025 (+19% YoY); 2026 guidance $450M-$470M.","Phase 3 ENCORE (ARIKAYCE in MAC lung) topline expected March/April 2026; sNDA planned H2 2026.","Phase 2b CEDAR (brensocatib in HS) topline expected Q2 2026; Phase 3 PALM-ILD (TPIP) initiated.","Additional Phase 3 TPIP studies in PAH, PPF, IPF planned for 2026; IND filings for INS1033, INS1203 expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-000778","json":"https://secwatch.observer/filing/0001140361-26-000778.json","markdown":"https://secwatch.observer/filing/0001140361-26-000778.md","text":"https://secwatch.observer/filing/0001140361-26-000778.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126000778/0001140361-26-000778-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126000778/ef20062540_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:01:51.038912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}